- Home
- BNTX vs EQR Comparison
BNTX vs EQR Comparison
Compare BNTX & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTX
- EQR
- Stock Information
- Founded
- BNTX 2008
- EQR 1993
- Country
- BNTX Germany
- EQR United States
- Employees
- BNTX N/A
- EQR N/A
- Industry
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- EQR Real Estate Investment Trusts
- Sector
- BNTX Health Care
- EQR Real Estate
- Exchange
- BNTX Nasdaq
- EQR Nasdaq
- Market Cap
- BNTX 23.9B
- EQR 26.4B
- IPO Year
- BNTX 2019
- EQR 1993
- Fundamental
- Price
- BNTX $113.85
- EQR $72.44
- Analyst Decision
- BNTX Strong Buy
- EQR Buy
- Analyst Count
- BNTX 15
- EQR 19
- Target Price
- BNTX $143.50
- EQR $76.61
- AVG Volume (30 Days)
- BNTX 659.5K
- EQR 1.5M
- Earning Date
- BNTX 11-04-2024
- EQR 01-28-2025
- Dividend Yield
- BNTX N/A
- EQR 3.74%
- EPS Growth
- BNTX N/A
- EQR 35.67
- EPS
- BNTX N/A
- EQR 2.44
- Revenue
- BNTX $3,390,698,192.00
- EQR $2,940,829,000.00
- Revenue This Year
- BNTX N/A
- EQR N/A
- Revenue Next Year
- BNTX N/A
- EQR $4.04
- P/E Ratio
- BNTX N/A
- EQR $29.64
- Revenue Growth
- BNTX N/A
- EQR 3.33
- 52 Week Low
- BNTX $76.53
- EQR $57.33
- 52 Week High
- BNTX $131.49
- EQR $78.83
- Technical
- Relative Strength Index (RSI)
- BNTX 48.71
- EQR 47.25
- Support Level
- BNTX $109.52
- EQR $69.35
- Resistance Level
- BNTX $115.34
- EQR $72.12
- Average True Range (ATR)
- BNTX 4.24
- EQR 1.35
- MACD
- BNTX -0.72
- EQR -0.13
- Stochastic Oscillator
- BNTX 27.24
- EQR 61.31
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.